Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02302339 · ClinicalTrials.gov registry record · Phase 2
A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma
A Phase 2 study, sponsored by Celldex Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 132
- Enrollment target
NCT02302339 is a Phase 2 study that was terminated before completion, run by Celldex Therapeutics. The registered enrollment target is 132 participants.
The verdict
NCT02302339, a Phase 2 study, was terminated before completion, sponsored by Celldex Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 132 participants
- Enrollment target
Study Summary
This study will examine the effectiveness and safety of glembatumumab vedotin as monotherapy or in combination with immunotherapies in patients with advanced melanoma.
Interventions
- DRUG glembatumumab vedotin
- DRUG glembatumumab vedotin and varlilumab
- DRUG glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab)
- DRUG glembatumumab vedotin and CDX-301
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2014-11 |
| Est. Completion | 2018-10-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02302339
The ClinicalTrials.gov registry entry for NCT02302339 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celldex Therapeutics, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which glembatumumab vedotin is the first listed.
NCT02302339 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02302339 about?
NCT02302339 is a clinical study titled "A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma". This study will examine the effectiveness and safety of glembatumumab vedotin as monotherapy or in combination with immunotherapies in patients with advanced melanoma.
What is the current status of trial NCT02302339?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 132 participants. The study started on 2014-11. Estimated completion is 2018-10-03.
What interventions are being tested in trial NCT02302339?
The interventions under investigation include: glembatumumab vedotin (DRUG), glembatumumab vedotin and varlilumab (DRUG), glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab) (DRUG), glembatumumab vedotin and CDX-301 (DRUG).
Who is sponsoring clinical trial NCT02302339?
This trial is sponsored by Celldex Therapeutics, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.